About us

CryoTherapeutics

Console
Reducing heart attack risk
Catheter
Procedure
We are developing a novel, minimally invasive, catheter-based cryotherapy system (CTS) designed to target coronary vulnerable plaques—a major underlying cause of myocardial infarction (MI) and responsible for approximately 75% of fatal cardiac events.

High-risk plaque

Inflammatory atherosclerotic processes lead to high-risk plaque in coronary arteries and are the major cause of heart attack. The majority of heart attacks occur in patients with a coronary plaque lesion that currently is not severe, presents little to no symptoms, and is therefore hard to diagnose at-risk patients.

High-Risk plaque lesions present often in young patients and progresses often without specific symptoms; it can therefore be challenging to diagnose patients. Development and progress in CCTA imaging, and its growing uptake in routine cardiological practice will allow earlier non-invasive detection of high-risk plaque.

Use of stents to treat high-risk plaque carries particular risks and uncertain outcomes.

We are

An early-stage European innovator developing a catheter for use by interventional cardiologists to treat atherosclerotic plaque that causes heart attack by delivering cryoenergy to the coronary arteries.

Management Team

Dr. John Yianni
CEO and co-founder

Danny Detiège
VP Clinical Affairs

Julie Humblet
Quality Manager

Richard Meaney
R&D Manager Catheter Development

Mauro Turturici
R&D Manager Console Development

Emmanuel Dagneaux
Finance and Administration Manager

Board of Directors

Eric Brandt

Rainer Christine

Dr. Jaochim Rautter

Karlheinz Schmelig

Florian Stinauer

Alfred Wong